Newly Activated Clinical Trials

This is a listing of clinical trials recently activated by the University of Illinois Cancer Center Clinical Trials Office for patient enrollment. Click the study links below to learn details regarding the studies on clinicaltrials.gov. You can also search for other clinical trials on our website. For more information or questions about a study, email [email protected] or call 312-355-5112.

---

Protocol Title: BMT-13: A Phase II Study of Intensity Modulated Total Marrow Irradiation (IM-TMI) in Addition to Myeloablative Fludarabine/Busulfan and Post-Transplant Cyclophosphamide (PTCY) for Fully HLA-Matched and Partially-HLA Mismatched Allogeneic Transplantation Patients with High-Risk AML, CML and MDS

Sponsor: University of Illinois Chicago (UIC)

Principal Investigator: Matias Sanchez, MD

---

Protocol Title: EA3231: A Randomized Phase III Study of BRAF-Targeted Therapy Vs Cabozantinib in RAI-Refractory Differentiated Thyroid Cancer With BRAF V600Em

Sponsor: ECOG-ACRIN

Principal Investigator: Frank Weinberg, MD, PhD

---

Protocol Title: ABK-CA-PROT-85: Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC)

Sponsor: ABK Biomedical, Inc

Principal Investigator: Ron Gaba, MD, MS

---

Protocol Title: EA7222: A Randomized Phase III Trial of Doxorubicin + Pembrolizumab Versus Doxorubicin Alone for the Treatment of Undifferentiated Pleomorphic Sarcoma (UPS) and Related Poorly Differentiated Sarcomas

Sponsor: ECOG-ACRIN

Principal Investigator: VK Gadi, MD, PhD

---

Protocol Title: A052101: A Randomized Phase 3 Trial Of Continuous Vs. Intermittent Maintenance Therapy With Zanubrutinib As Upfront Treatment In Older Patients With Mantle Cell Lymphoma

Sponsor: Alliance

Principal Investigator: Carlos Galvez, MD

---

Protocol Title: S2303: Randomized Phase II/III Trial of 2nd Line Nivolumab + Paclitaxel + Ramucirumab versus Paclitaxel + Ramucirumab in Patients with PD-L1 CPS equal or less than 1 Advanced Gastric and Esophageal Adenocarcinoma (PARAMUNE)

Sponsor: Alliance

Principal Investigator: Yolande Chen, MD

---